Tradestie Institutional Equity Comparison Engine
DNLI vs BHVN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BHVN Overall Edge
BHVN Captures Institutional Edge (3โ0 Pillars ยท 3โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Biohaven Ltd. (BHVN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, DNLI trades at N/M Forward P/E with -2481.1% operating margin (-100.0% YoY revenue) versus BHVN at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, DNLI sits in BREAKDOWN (27th %ile IV; Dealer Gamma Walls on Pro) against BHVN sits in CONSOLIDATION (18th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
DNLI N/M vs BHVN N/M Fwd P/E
Growth & Margin Winner
BHVN
Op Margin -2481.1% vs 0.0% ยท YoY -100.0% vs +0.0%
Momentum & Technical Winner
BHVN
1Y +6.9% vs +72.1% ยท 52W Pos 25% vs 59%
Options & Structure Winner
BHVN
BREAKDOWN (27th %ile IV) vs CONSOLIDATION (18th %ile IV)
DNLI
NASDAQ
Denali Therapeutics Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$18.33
-2.19% 1D
Market Cap
$3.0B
1M Return
+4.09%
1Y Return
+6.88%
Forward P/E
N/M
Unified AI Score
55.5 / 100
HOLD
Tech 44.0
Fund 55.0
Flow 66.0
Mom 50.0
BHVN
NYSE
Biohaven Ltd.
Pharmaceutical Preparations
$13.90
+0.62% 1D
Market Cap
$2.1B
1M Return
+28.99%
1Y Return
+72.09%
Forward P/E
N/M
Unified AI Score
42.1 / 100
HOLD
Tech 15.0
Fund 42.0
Flow 68.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
DNLI +6.88%
BHVN +72.09%
Spread: +65.21 pp (BHVN Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
DNLI TTM Op. Margin: -2481.1%
BHVN TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DNLI vs BHVN. Trailing 12-month operating profitability (DNLI -2481.1% vs BHVN 0.0%) and valuation multiples (DNLI N/M vs BHVN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | DNLI | BHVN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.0B | $2.1B | Larger Scale | DNLI |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -100.0% | +0.0% | Higher Growth | BHVN |
| Operating Margin (TTM) Profitability | -2481.1% | 0.0% | Higher Margin | BHVN |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -33.9% | -799.5% | Higher ROE | DNLI |
| 52-Week Range Position Momentum | 25% ($15โ$27) | 59% ($8โ$18) | Stronger Trend | BHVN |
| Beta / 30D Volatility Risk Regime | 1.36ฮฒ ยท 48% Vol | 1.41ฮฒ ยท 111% Vol | Lower Realized Risk | DNLI |
| Unified Institutional Score Composite Signal | 55.5 / 100 (HOLD) | 42.1 / 100 (HOLD) | Higher Composite | DNLI |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full DNLI vs BHVN Buy Guide
DNLI
BREAKDOWN
91d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
27th %ile
IV Regime
Balanced (25thโ60th %ile)
BHVN
CONSOLIDATION
91d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
18th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither DNLI nor BHVN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.